{
    "score": [
        1.0
    ],
    "extracted": [
        3
    ],
    "abstract": [
        "htg molecular diagnostics lowered to `` hold '' at zacks investment research ."
    ],
    "id": "734363.train",
    "article": [
        "zacks investment research downgraded shares of htg molecular diagnostics from a buy rating to a hold rating in a research report sent to investors on friday morning . according to zacks , `` htg molecular diagnostics , inc. . is engaged in developing and marketing a technology platform which consists of instrumentation , consumables and software analytics for sample profiling applications including tumor profiling , molecular diagnostic testing and biomarker development . its products include htg edge system , htg edge assays and htg assay direct . htg molecular diagnostics , inc. . is headquartered in tucson , arizona . ",
        "`` other research analysts also recently issued research reports about the company . canaccord genuity increased their price target on htg molecular diagnostics to $ 5.00 in a research note on friday . hc wainwright set a $ 6.00 target price on htg molecular diagnostics and gave the stock a buy rating in a research note on friday . finally , valuengine upgraded htg molecular diagnostics from a strong sell rating to a sell rating in a research note on monday , october 23rd . one analyst has rated the stock with a sell rating , two have issued a hold rating and two have issued a buy rating to the company 's stock . ",
        "htg molecular diagnostics presently has a consensus rating of hold and an average target price of $ 4.88 . shares of htg molecular diagnostics traded down $ 0.56 during trading on friday , hitting $ 3.47 . the stock had a trading volume of 6,628,400 shares , compared to its average volume of 5,032,625 . htg molecular diagnostics has a 1 year low of $ 1.20 and a 1 year high of $ 13.25 . the stock has a market cap of $ 42.24 and a price-to-earnings ratio of -1.36 . an institutional investor recently raised its position in htg molecular diagnostics stock . ",
        "vanguard group inc. . lifted its position in shares of htg molecular diagnostics inc by 38.9 % during the second quarter , according to the company in its most recent filing with the securities and exchange commission . the institutional investor owned 135,234 shares of the medical research company 's stock after buying an additional 37,841 shares during the period . vanguard group inc. . owned about 1.42 % of htg molecular diagnostics worth $ 359,000 as of its most recent sec filing . hedge funds and other institutional investors own 15.15 % of the company 's stock . illegal activity warning : `` htg molecular diagnostics lowered to `` hold '' at zacks investment research '' was first posted by watch list news and is the sole property of of watch list news . ",
        "if you are viewing this news story on another publication , it was illegally stolen and reposted in violation of us and international copyright and trademark law . the correct version of this news story can be viewed at molecular diagnostics company profilehtg molecular diagnostics , inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling . the company 's htg edge and htg edgeseq platforms , consisting of instrumentation , consumables and software analytics , are used in sample profiling applications , including tumor profiling , molecular diagnostic testing and biomarker development . ",
        "get a free copy of the zacks research report on htg molecular diagnostics for more information about research offerings from zacks investment research , visit zacks . com .   "
    ]
}